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ABSTRACT In a structured survey of all major chicken-meat producers in Australia,
we investigated the antimicrobial resistance (AMR) and genomic characteristics of
Campylobacter jejuni (n  108) and C. coli (n  96) from cecal samples of chickens at
slaughter (n  200). The majority of the C. jejuni (63%) and C. coli (86.5%) samples
were susceptible to all antimicrobials. Fluoroquinolone resistance was detected
among both C. jejuni (14.8%) and C. coli (5.2%), although this only included three se-
quence types (STs) and one ST, respectively. Multidrug resistance among strains of
C. jejuni (0.9%) and C. coli (4.1%) was rare, and fluoroquinolone resistance, when
present, was never accompanied by resistance to any other agent. Comparative ge-
nome analysis demonstrated that Australian isolates were found dispersed on differ-
ent branches/clusters within the international collection. The major fluoroquinolone-
resistant STs of C. jejuni (ST7323, ST2083, and ST2343) and C. coli (ST860) present in
Australian chickens were similar to those of international isolates and have been re-
ported previously in humans and animals overseas. The detection of a subpopula-
tion of Campylobacter isolates exclusively resistant to fluoroquinolone was unex-
pected since most critically important antimicrobials such as fluoroquinolones are
excluded from use in Australian livestock. A number of factors, including the low
level of resistance to other antimicrobials, the absence of fluoroquinolone use, the
adoption of measures for preventing spread of contagion between flocks, and par-
ticularly the genomic identities of isolates, all point to humans, pest species, or wild
birds as being the most plausible source of organisms. This study also demonstrates
the need for vigilance in the form of surveillance for AMR based on robust sampling
to manage AMR risks in the food chain.
IMPORTANCE Campylobacter is one of the most common causes of gastroenteritis
in humans, with infections frequently resulting from exposure to undercooked poul-
try products. Although human illness is typically self-limiting, a minority of cases do
require antimicrobial therapy. Ensuring that Campylobacter originating from meat
chickens does not acquire resistance to fluoroquinolones is therefore a valuable out-
come for public health. Australia has never legalized the use of fluoroquinolones in
commercial chickens and until now fluoroquinolone-resistant Campylobacter has not
been detected in the Australian poultry. This structured survey of meat chickens de-
rived from all major Australian producers describes the unexpected emergence of
fluoroquinolone resistance in Campylobacter jejuni and C. coli. Genetic characteriza-
tion suggests that these isolates may have evolved outside the Australian poultry
sector and were introduced into poultry by humans, pest species, or wild birds. The
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findings dramatically underline the critical role of biosecurity in the overall fight
against antimicrobial resistance.
KEYWORDS AMR, Australia, Campylobacter, Campylobacter coli, Campylobacter jejuni,
antimicrobial resistance, chicken, fluoroquinolone, genome analysis, livestock
Campylobacter jejuni and C. coli are common inhabitants of the gastrointestinal tractsof animals and are regarded as the most frequent causes of acute bacterial enteritis
in humans (1–4). The main pathways by which humans acquire infection (1, 5) are the
consumption of undercooked poultry meat, food cross-contaminated with raw poultry
product, water contaminated with Campylobacter from animals or humans, and direct
contact with animals or human clinical campylobacteriosis cases (4, 6). Campylobacte-
riosis in humans is usually a self-limiting condition involving diarrhea, abdominal
cramping, and fever of up to 2 weeks’ duration (1, 2). However, neonates, the elderly,
and individuals with immune disorders might develop more serious symptoms that
necessitate antimicrobial therapy (2, 7, 8). In such cases, macrolides such as erythro-
mycin are the first choice for treatment, although in many countries the use of
ciprofloxacin (a fluoroquinolone) is used preferred on an empirical basis (2). The
emergence of resistance to fluoroquinolones in Campylobacter spp., combined with the
high incidence of Campylobacter infections in humans, is a major concern for public
health (9).
Many countries have experienced a steady increase in the proportion of Campylo-
bacter isolates from humans and animals expressing resistance to fluoroquinolones (10,
11). A recent European Union report on health aspects of antimicrobial resistance (AMR)
reported high rates of fluoroquinolone resistance among C. jejuni from broilers (66.9%)
and humans (54.6%) (12). A recent review by Sproston et al. (11) also highlighted a
global trend in increasing fluoroquinolone resistance among Campylobacter isolates
from both humans and poultry (11). These events have been attributed to the wide-
spread use of fluoroquinolones in the livestock sector, although in some cases the
maintenance of fluoroquinolone-resistant Campylobacter strains in livestock has oc-
curred without any direct selection pressure from use of fluoroquinolones (10, 11). A
distinctly different circumstance exists in Australia, where the rate of detection of
fluoroquinolone resistance in Campylobacter spp. from humans is very low (2, 10, 13)
and where most such infections are thought to be acquired when traveling abroad (13).
The low burden of human infection with fluoroquinolone-resistant Campylobacter has
also been attributed to the exclusion of this class from registered products available for
use in food animals in Australia, as well as the protection provided by geographic
isolation and strict quarantine measures at the national border (14, 15).
Although fluoroquinolones are not registered for use in any food-producing animals
(including meat chickens) in Australia, it is essential to determine whether there has
been sporadic emergence of fluoroquinolone-resistant Campylobacter, as well as to
identify the frequency of resistance to other antimicrobials. Here, we sought to obtain
an epidemiologically sound collection of C. jejuni and C. coli isolates representative of
strains harbored by the Australian meat chicken flock and to investigate their antimi-
crobial resistance and genomic characteristics.
RESULTS
Antimicrobial resistance characterization. A total of 204 individual isolates of
Campylobacter (108 C. jejuni isolates and 96 C. coli isolates) were isolated from 200 pooled
cecal samples. The antimicrobial resistance patterns for C. jejuni and C. coli based on
epidemiologic cutoff values (ECOFFs) are shown in Fig. 1 and 2. Full MIC distributions are
shown in Tables S2 and S3 in the supplemental material.
(i) Campylobacter jejuni. Of the 108 C. jejuni isolates, the most commonly detected
resistance was to tetracycline (22.2%), followed by resistance to the quinolones cipro-
floxacin (14.8%) and nalidixic acid (14.8%) (Fig. 1). In addition, one C. jejuni isolate was
also resistant to macrolides (both azithomycin and erythromycin). No resistance was
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detected to any of the antimicrobials tested in 63% of C. jejuni isolates (Table 1), and
none were resistant to florfenicol and gentamicin (Fig. 1). Only one C. jejuni isolate was
classified as having a multidrug-resistant (MDR) phenotype (Table 1). The MDR C. jejuni
isolate demonstrated resistance to lincosamide, macrolide, and tetracycline.
(ii) Campylobacter coli. Campylobacter coli isolates displayed less overall resistance
to tested antimicrobials, with 86.5% of the 96 isolates susceptable to all tested
antimicrobials (Table 2). Commonly detected phenotypic resistance was to ciprofloxa-
cin, nalidixic acid, azithromycin, erythromycin and clindamycin all at 5.2% (Fig. 2).
Resistance to telithromycin (4.2%) and tetracylcine (3.1%) was also identified. None of
the isolates were resistant to florphenicol or gentamicin.
Genomic characterization. (i) Campylobacter jejuni. The C. jejuni isolates demon-
strate high genetic diversity, with the isolates belonging to 32 known sequence types




















FIG 2 Antimicrobial resistance patterns for C. coli (n  96) isolated from Australian meat chickens. The proportion susceptible is shown in blue, and the




















FIG 1 Antimicrobial resistance patterns for C. jejuni (n  108) isolated from Australian meat chickens. The proportion susceptible is shown in blue, and the
proportion resistant is shown in red.
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ST2083 (n  8), ST535 (n  7), ST4896 (n  7), and 9432 (n  7) (see Table S4 in the
supplemental material).
When principal component analysis (PCA) based on total gene content was performed
on Australian isolates and an international collection of C. jejuni isolates, no distinct
clustering was observed for Australian isolates (see Fig. S1 in the supplemental material).
Similarly, by using phylogenetic analysis we found that the Australian isolates were dis-
persed among different branches within the international collection. Moreover, the Aus-
tralian strains resistant to fluoroquinolone (ST2083) were found on the same node with
similar strain types of the international collection (Fig. 3). Genetic analysis indicated that all
fluoroquinolone-resistant isolates possessed a mutation in the DNA gyrase A subunit
(Thr86¡Ile) that was absent from all susceptible isolates. Fluoroquinolone-resistant C. jejuni
belonged to sequence types ST7323 (n  9), ST2083 (n  8), and ST2343 (n  1). Minimum
spanning tree (MST) analysis demonstrated that the fluoroquinolone-resistant STs are not
part of clonal clusters; with ST7323, there were a minimum of four locus variants from its
nearest ST, and with ST2082, five locus variants separate (Fig. S2A). Phylogenetic analysis of
the fluoroquinolone-resistant C. jejuni isolates revealed low levels of diversity between the
STs, with 10 to 90 single nucleotide polymorphism (SNP) differences in the core genome
between ST2083 and ST7323 (Fig. S3). Analysis of whole-genome sequencing highlighted
a low carriage of resistance genes in C. jejuni isolates, with tetO identified in 28.4% (n  23)
of the isolates (Fig. 3), supporting the phenotypic resistance to tetracycline; 64.8% (n  68)
of the isolates carried the blaOXA gene.
(ii) Campylobacter coli. Of the 96 C. coli isolates, one was a mixed C. jejuni-C. coli
culture and was subsequently excluded from whole-genome sequencing. Among
the 95 remaining C. coli isolates, the predominant sequence types were ST1181
(n  14), ST827 (n  9), ST3985 (n  9), ST825 (n  8), ST832 (n  7), and ST860
(n  7), with a further five known sequence types identified, as well as 12 new
sequence types (Table S5).
The PCA for total gene content revealed no distinct clustering for Australian isolates
compared to the international collection (Fig. S4), a finding corroborated by the
phylogenetic analysis of core gene content, where the Australian isolates were dis-
persed on different branches with the international collection (Fig. 4). The Australian
strains resistant to fluoroquinolone (ST860) were found on the same node with similar
strain types of the international collection. A separate phylogenetic analysis was also
performed for C. coli strains of the Australian collection that resulted in three clades
with high levels of diversity between each clade (data not shown), with one clade
(Australian clade 1) being particularly divergent from Australian clades 2 and 3 (24,000
and 26,500 SNP differences, respectively). The fluoroquinolone-resistant strains be-
longed to clade 3. All of the fluoroquinolone-resistant C. coli isolates (5.2%) belonged
to ST860; all of these resistant isolates carried the Thr86¡Ile mutation in the DNA
TABLE 1 Class-based antimicrobial resistance profiles of C. jejuni isolates (n  108)
Resistance profilea No. of resistances No. of isolates % of total
nil 0 68 63.0
qui 1 16 14.8
tet 1 23 21.3
lin_mac_tet 4 1 0.9
amac, macrolides; nil, no resistance; qui, quinolones; lin, lincosamide; tet, tetracycline.
TABLE 2 Class-based antimicrobial resistance profiles of C. coli isolates (n  96)
Resistance profilea No. of resistances No. of isolates % of total
nil 0 83 86.5
qui 1 5 5.2
tet 1 3 3.1
lin_mac 5 5 5.2
amac, macrolides; nil, no resistance; qui, quinolones; lin, lincosamide; tet, tetracycline.
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gyrase subunit associated with fluoroquinolone resistance (Fig. S5). In contrast to
fluoroquinolone-resistant C. jejuni isolates, MST analysis appeared to indicate that
ST860 may be part of clonal complex linked by single- and double-locus variants
involving STs 825, 832, 9417, 9418, 9419, and 3985 (Fig. S2B). There were two isolates
belonging to ST860 that had no phenotypic resistance against fluoroquinolone and no
mutation for fluoroquinolone resistance (Table S5). Only a single isolate belonging to
ST9420 showed a tet resistance gene; 72 isolates were positive for the blaOXA gene.
Core genome diversity within ST860 revealed fluoroquinolone-susceptible and
fluoroquinolone-resistant strains delineated into two major clonal groups. Fluoro-
quinolone-resistant isolates had core genome SNP differences ranging between 241
and 591 and were between 677 and 736 SNPs different from the susceptible isolates,
which were separated by only 214 SNPs (Fig. S5).
DISCUSSION
In this study, we report the phenotypic antimicrobial resistance and genomic
characteristics of C. jejuni and C. coli isolated from a national survey of Australian meat
chickens at slaughter, providing an update to surveillance performed in Australian
poultry more than 10 years ago (16). Several of our findings stand to progress our
understanding of the potential for antimicrobial-resistant C. coli and C. jejuni to ad-
versely impact on humans in Australia. First, we detected low rates of both single-drug
antimicrobial resistance and MDR phenotypes, which distinguishes this work from
many similar studies performed abroad (10–13). Second, this study reports the detec-
tion and genomic characterization of fluoroquinolone-resistant C. jejuni and C. coli in
chickens in Australia; these organisms have achieved widespread colonization of
commercial flocks without evidence of direct selection pressure from the use of
FIG 3 Core genome phylogeny of the 105 Australian (blue) and 628 international collection (red) isolates
of C. jejuni. The Australian isolates are dispersed on different branches, along with the international
collection. The presence of two resistance genes (tet and blaOXA) found among isolates are indicated as
black squares. Moreover, the Australian ciprofloxacin-resistant isolates (ST2083 shown as purple squares)
are found on the same node with a similar strain type from the international collection.
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fluoroquinolones. Also, the major STs associated with fluoroquinolone-resistant C. jejuni
and C. coli in these Australian isolates from chickens have been reported previously in
humans and animals internationally, and the presence of three separate STs in our data
set that cluster closely with international strains suggests that at least some of these STs
may have been introduced into Australian meat chickens, perhaps through incursions
of wild birds or workers returning from overseas. Finally, a high degree of genetic
diversity is present in the Campylobacter spp. recovered, as indicated by the number of
STs present for both C. jejuni (32 STs) and C. coli (10 STs).
Relatively low levels of antimicrobial resistance were observed among both C. jejuni
and C. coli strains, with no resistance detected to any of the antibiotics tested in 63%
of the C. jejuni isolates and 86.5% of the C. coli isolates. The results for C. jejuni are
comparable to the most recent surveillance findings available from Scandinavian
countries (17–19); these are jurisdictions noted for their well-established and strict
control of antimicrobial use in animals (20). Only 0.9% (1/108) of C. jejuni and 5.2%
(5/96) of C. coli isolates were resistant to macrolides (erythromycin and azithromycin),
one of the key antimicrobial classes used for treating human campylobacteriosis, and
none of the isolates carried an erm gene or contained known SNPs in the 23S rRNA
genes associated with resistance. The overall frequency of erythromycin resistance
among Campylobacter spp. in the 2004 survey was 19.9% (16). In the 2004 survey,
determination of Campylobacter to the species level was not performed (16), but
despite this, the current survey shows a substantial reduction in the carriage of
macrolide resistance among Campylobacter isolates. A low level of MDR phenotypes
was identified among both C. coli (4.2%; four isolates) and C. jejuni (0.9%; one isolate)
FIG 4 Core genome phylogeny of the 82 Australian (blue) and 647 international collection (red) isolates of C. coli.
The Australian isolates are found dispersed on different branches, along with the international collection. The
presence of two resistance genes (tet and blaOXA) found among isolates are indicated as black squares. Moreover,
the Australian ciprofloxacin-resistant isolates (ST860 shown as purple squares) are found on the same node with
a similar strain type from the international collection.
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samples, none of which included resistance to fluoroquinolones, but all of which
included resistance to macrolides. These outcomes highlight the benefit of the long-
standing conservative approach to registration of antimicrobials for use in food animals
in Australia.
The four most prominent of the 32 sequence types detected in the C. jejuni isolates
from this study have previously been found in humans, with ST2083 and ST535 also
found in poultry and ST7323 and ST535 previously reported in Australia (21). The high
number of different sequence types detected and the range of hosts and countries
where these STs have been detected reveals the high level of diversity in the popula-
tion of Australian C. jejuni clones. With regard to C. coli, the six main sequence types
have all been isolated from humans and livestock previously with ST825, ST827, ST832,
ST860, and ST1181 having been reported to cause gastroenteritis in humans. ST825,
ST1181, and ST3985 have been isolated from Australian livestock and ST3985 and
ST1181 have been isolated from human cases in Australia, with ST832 and ST825 not
previously isolated from Australia, as reported to the PubMLST database (21).
The detection of ciprofloxacin resistance in this study was an unexpected finding,
given that fluoroquinolones are excluded from use in Australian food animals. Addi-
tional evidence that fluoroquinolone resistance did not evolve as a result of local
selection pressure is the finding that the responsible mutations are not accompanied
by MDR in any isolates. However, the occurrence of fluoroquinolone resistance in the
absence of any other resistance phenotype in Campylobacter from meat chickens is a
phenomenon also observed in other countries with similarly constrained use of fluo-
roquinolones in food animals (20). For example, ciprofloxacin-resistant C. jejuni was
present in 2016 Danish (17) and 2015 U.S. (22) surveillance data at the rates of 23 and
50%, respectively. It is possible that the fluoroquinolone-resistant C. jejuni and C. coli
detected in multiple locations globally evolved in wildlife with environmental exposure
to fluoroquinolones or from a production system where fluoroquinolones were pre-
dominantly used as first-line therapy (23). Recent reports from New Zealand demon-
strated that fluoroquinolone resistance detected there among poultry was attributable
to the emergence of a new clone of C. jejuni (ST6964) that was resistant to both
ciprofloxacin and tetracycline (24). It has been hypothesized that this clone was
potentially introduced via exposure to other species (human or other livestock) rather
than due to direct antimicrobial use because fluoroquinolones are not registered for
use in poultry in New Zealand. Recent Australian studies in livestock have similarly
revealed that bacteria expressing resistance to critically important antimicrobials were
likely introduced along pathways involving reverse zoonosis (human-animal transmis-
sion) or wild birds (20, 25–29). This included the detection of community- and livestock-
associated methicillin-resistant Staphylococcus aureus (ST93 and ST398) in pigs (26, 28),
community-associated MRSA ST-1 in dairy cows (27), globally disseminated fluoroquin-
olone and extended-spectrum cephalosporin-resistant E. coli, and plasmids in Austra-
lian pigs in the absence of fluoroquinolone use (20, 29).
Importantly, with the exception of horses, the national quarantine boundary of
Australia is designed to be impervious to farm animals and unprocessed animal
products, thus excluding these pathways as a route of acquisition. Campylobacter
undergoes significant horizontal transmission, and it has been shown that fluoroquin-
olone resistance associated with SNPs in the gyrA region can be acquired via transfor-
mation from resistant isolates (30). However, it would appear that horizontal transfer of
genetic material is not the key mechanism involved in resistance, and results from this
study, particularly in the case of C. jejuni where fluoroquinolone-resistant isolates
appear quite discrete based on MST analysis, would indicate that these STs are
separate, and it is reasonable to hypothesize that multiple introductions of clones or
episodes of resistance development have occurred. In summary, we postulate that the
fluoroquinolone-resistant C. jejuni and C. coli detected in this study were introduced
into the Australian chicken industry by mechanisms involving humans and/or wildlife
and that this type of transmission might be occurring more commonly than has
previously been described. In addition, the role of other incursion pathways, such as
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contaminated water supplied to the birds for drinking and rodents as reservoirs in
farms, also requires further consideration and investigation.
Whole-genome sequence analysis demonstrated that all fluoroquinolone resistant C.
jejuni and C. coli isolates possessed the single point mutation (Thr86¡Ile) in the DNA
gyrase A subunit. Mutations within gyrA are associated with fluoroquinolone resistance
in multiple bacterial species, with this single nucleotide polymorphism alone conferring
fluoroquinolone resistance in Campylobacter. The fluoroquinolone-resistant C. jejuni
belonged to the ST7323 (n  9), ST2083 (n  8), and ST2343 (n  1) sequence types,
which have all been previously isolated from chickens (ST7323 and ST2343 in New
Zealand and ST2083 in the United States) (24, 31). These three sequence types have
also been isolated from humans (32, 33). Comparative genomic analysis of C. jejuni
isolates with international isolates available revealed that fluoroquinolone-resistant C.
jejuni isolates belonging to ST2083 were closely related to ST2083 strains isolated from
chickens in the United States. The four U.S. C. jejuni isolates belonging to ST2083 all
carried the mutation in DNA gyrA. However, the lack of genomic data available limits
our ability to further investigate the origin of these clones.
ST860 was the only sequence type identified among the fluoroquinolone-resistant
C. coli, with this sequence type previously reported in chickens and humans from
Vietnam and Japan, respectively (34, 35). With the lack of comprehensive whole-
genome sequence and associated source data on epidemiologically relevant sample
sizes from different countries that have reported these fluoroquinolone-resistant C.
jejuni clones, it is not feasible to perform comparative genome analysis to identify the
origins of the fluoroquinolone-resistant isolates identified in this study. Analysis within
this sample set demonstrates three fluoroquinolone-resistant C. jejuni clones, which all
have low levels of SNP differences within the clones themselves, inferring recent
emergence. This is not the case with the C. coli, with the resistant and susceptible
strains of ST860 being divergent from one another, suggesting a less recent emergence
of the resistant clone.
In conclusion, this study demonstrates a favorable AMR status among the majority
of C. jejuni and C. coli isolates with regard to resistance to key antimicrobials important
to human health. However, the present study reveals the emergence of fluoroquino-
lone-specific drug resistance in small subpopulation of C. jejuni and C. coli among
Australian isolates from the guts of meat chickens in the absence of fluoroquinolone
use. The genomic characterization and phenotypic resistance to fluoroquinolones alone
indicates that these isolates may have been introduced to Australian meat chickens via
pathways involving reverse zoonosis, pest animals, or wild birds. Follow-up studies to
determine circulating Campylobacter in wild birds and rodents frequenting production
sites and drinking water provided for birds may provide some insight into the origin
and ecology of resistant clones.
MATERIALS AND METHODS
Study design. The study was conducted as part of an Australia-wide study (36, 37) based on the
collection of composites of five whole cecal pairs from approximately 4- to 7-week-old meat chickens at
slaughter between June and November 2016. A total of 200 pooled cecal composites were collected from
all major Australian meat chicken producers. The sampling followed a two-stage (cluster based) design
involving all major processors of meat chickens in Australia (20 plants representing 95% of production)
as the first stage of sampling. Within each plant, the number of cecal composites collected (the second
stage of sampling) was proportional to the plant’s processing volume. No more than one cecal composite
was obtained from any single processing batch, and each cecal composite was collected immediately
postevisceration from midway through the batch (i.e., not the first or last chickens processed from a
batch). To construct each composite, only viscera that were not visibly contaminated with digesta were
removed with their intact cecal pair, in accordance with the protocol described by NARMS (USA) (38).
Each cecal pair was removed from the viscera using sterile scissors at the sphincter between the cecum
and the small intestines, and one cecum of each pair was placed into a labeled container (70-ml sterile
screw-top containers). This continued until each container held a total of five individual ceca from a
single processing batch. Consignments of samples were packed with ice packs and dispatched to the
laboratory, where the time elapsed since collection and temperature inside the shipping container were
both recorded. Samples that arrived more than 24 h after collection or at a temperature above 8°C were
discarded, and a notification was sent to the processing plant for replacement samples to be forwarded.
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Bacterial isolation and identification. The ceca from each sample were placed into individual
stomacher bags and homogenized by stomaching for 60 s and then left standing at room temperature
for 5 min for gravity settling of large particles. Campylobacters were isolated using in 90-ml aliquots of
Campylobacter selective Bolton broth (Thermo Fisher Scientific) by adding 10 g of homogenized sample,
followed by shaking to suspend the particles. For samples that were obtained 12 h postsampling,
100 l was streaked direct from Bolton broth-homogenate onto CSK (Skirrow; bioMérieux) and CFA
(Campy Food Agar; bioMérieux) agar and incubated at 42°C for 48 h. For samples that were obtained 12
h postsampling, the direct streaking method was performed, along with a preliminary incubation of the
Bolton broth-homogenate sample at 42°C for 48 h under microaerophilic conditions, prior to streaking
onto CSK and CFA agar.
Vitek 2 (bioMérieux) was initially used to verify the presence of Campylobacter species isolates
according to the manufacturer’s instructions. Further confirmation was then performed using MALDI-
TOFF (Bruker) by direct plating single colonies onto a matrix-assisted laser desorption ionization–time of
flight (MALDI-TOF) target plate, application of alpha-cyano-4-hydroxycinnamic acid matrix solution, and
exposure to laser deionization, followed by cross-referencing the output to the Bruker identification
library according to the standard manufacturer protocols (Bruker Microflex). From a pure subculture from
the original colony, bacteria were harvested for storage at 80°C on proprietarily modified cryo-beads
(Thermo Fisher Scientific) until further testing.
Antimicrobial susceptibility testing. One cryo-bead from each vial was placed onto a Columbia
sheep blood agar (Thermo Fisher Scientific) and incubated microaerophilically at 37°C for 48 h. A single
colony was then streaked onto a second Columbia sheep blood agar and incubated at 42°C for 24 h.
Antimicrobial susceptibility for the isolates was determined by the broth microdilution method using
the NARMS Campy Sensititre panel (Trek Diagnostics; Thermo Fisher Scientific) according to Clinical and
Laboratory Standards Institute guidelines adapted for the Sensititre system (39). The MIC results were
captured using the Vision System (Trek; Thermo Fisher Scientific), and results were interpreted and
verified independently by two laboratory scientists. The complete list of antimicrobials, along with the
concentration ranges that were tested, are listed according to their antimicrobial classes in Table S1 in
the supplemental material. Epidemiologic cutoff values (ECOFFs) were used as the basis of interpretation
in accordance with the current EUCAST protocol where possible (40). Quality control was performed
using C. jejuni ATCC 33560 throughout the study period. In the present study, isolates classified as
“non-wild type” based on ECOFF breakpoints are referred to as “resistant.” Isolates resistant to three or
more antimicrobial classes were classified as multidrug resistant (MDR).
Whole-genome sequencing. A total of 96 C. coli and 108 C. jejuni isolates were selected for
whole-genome sequencing. DNA extraction was performed on all isolates using a MagMAX multisample
DNA extraction kit (Thermo Fisher Scientific) according to the manufacturer’s instructions. DNA library
preparation was conducted by using an Illumina Nextera XT library preparation kit, with variation from
the manufacturer’s instructions for an increased time of tagmentation to 7 min. Library preparations were
sequenced on an Illumina Nextseq platform using a mid-output 2  150 kit. All read data have been
deposited in the NCBI database under accession number PRJNA509514. Genomic data were de novo
assembled using SPAdes (41), and the contigs were analyzed using the Centre for Genomic Epidemiology
(http://www.genomicepidemiology.org/) for the screening of multilocus sequence types. Quality checks
were performed on all sequenced isolates before analysis of phylogenetic trees and the presence of
antimicrobial-resistant and virulence genes. Totals of 82 C. coli and 105 C. jejuni isolates were passed for
quality using NASP pipelines using over 80% of quality breadth (42). The antimicrobial genes were
searched for and detected using resfinder with a cutoff value of 99% for the identity, with a coverage
of 100%. Virulence genes were detected by the Abricate program using the universal virulence finder
database with the cutoff of 99% identity and 100% coverage. Campylobacter isolates with unknown
sequence types were additionally searched against the pubMLST database (C. jejuni/C. coli v1.0) (21), with
new sequence types assigned. MST results were constructed based on MLST loci using the goeBURST full
MST profile within PHYLOViZ (43). The presence of known quinolone resistance region mutations was
detected using the Snippy tool (v3.2) in the Nullarbor bioinformatics pipeline (44), and the macrolide-
resistant isolates were manually checked for the presence of known resistance associated SNPs at
positions 2074 and 2075 of the 23S rRNA gene (45). The Campylobacter isolates detected in this study
were compared to an international collection of C. jejuni (n  627) and C. coli (n  647) strains previously
sequenced in the United States (UDA NARMS data [ENA study accession no. PRJNA292664] and USDA
FSIS data [ENA study accession PRJNA287430]) and Spain (46). Phylogenetic trees were constructed from
the extraction of all SNPs from the core genome using Snippy and Snippy core (47). ClonalFrameML was
used to remove potential recombination (48), and the adjusted core SNP alignment was used to produce
a maximum-likelihood tree using RAxML (49). The ggtree package in R was used to annotate phyloge-
netic trees (50).
Statistical analysis. Data were processed using custom scripts for converting plate reader output
into MIC tables. Proportions of colonies with traits of interest and the corresponding 95% exact binomial
confidence intervals were derived using the Clopper-Pearson method. All analysis was performed using
Stata v15.1 (StataCorp LLC, College Station, TX) or the R Statistical Package v3.5.1 (51).
Data availability. All read data were deposited in the NCBI database under accession number
PRJNA509514.
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